GPX4 and cancer: Based on the results of in silico analysis by the Cancer Therapeutics Response Portal (CTRP), CD98hc can be potentially susceptible to some repurposed inhibitors, such as thioredoxin-1 (Trx-1) inhibitor PX-12, GPX-4 inhibitors ML162 and ML-210, inhibitor of GPX-4 and ferroptosis activator (1S,3R)-RSL3, and PRIMA-1 (P53-dependent reactivation and induction of massive apoptosis) compound (Figure 4).